VBK - Vanguard Small Cap Growth Index Fund
| Previous Close | 164.37 |
| Open | 164.97 |
| Bid | 155.01 x 200 |
| Ask | 180.00 x 100 |
| Day's Range | 164.58 - 166.27 |
| 52 Week Range | 140.10 - 172.17 |
| Volume | 150,377 |
| Avg. Volume | 141,633 |
| Net Assets | 21.46B |
| NAV | 163.94 |
| PE Ratio (TTM) | N/A |
| Yield | 0.74% |
| YTD Return | 2.07% |
| Beta (3y) | 1.02 |
| Expense Ratio (net) | 0.07% |
| Inception Date | 2004-01-26 |
- Zacks•16 days ago
Should Guggenheim S&P SmallCap 600 Pure Growth ETF (RZG) Be on Your Investing Radar?
Style Box ETF report for RZG
- ETF Trends•2 months ago
Big Growth With Popular Small-Cap ETF
Small-cap stocks and the related exchange traded funds are often prized for their growth prospects and small-cap ETFs are explicitly dedicated to the growth factor, including the popular Vanguard Small-Cap ...
- InvestorPlace•2 months ago
7 of the Best Growth ETFs
Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs).
- Zacks•3 months ago
The Zacks Analyst Blog Highlights: Select Sector SPDR Technology, Vanguard Small-Cap Growth, iShares MSCI ACWI, EventShares U.S. Tax Reform and Vanguard Value
The Zacks Analyst Blog Highlights: Select Sector SPDR Technology, Vanguard Small-Cap Growth, iShares MSCI ACWI, EventShares U.S. Tax Reform and Vanguard Value
- Zacks•3 months ago
Amazing ETF Strategies for Skyrocketing Markets
We have highlighted some investing ideas that could prove extremely beneficial for investors this year in the bullish market.
Market Realist•3 months agoHow Is Bioverativ’s Eloctate Positioned Now?
A Snapshot of Bioverativ's Recent Performance
- InvestorPlace•4 months ago
ETFs to Bet on the Final Tax Bill: What’s Hot, What’s Not
After negotiating on two versions of the bill already passed by the House and Senate, Republicans unveiled their final tax bill — which would reshape the tax code in three decades, making America more competitive. The Congress will vote on the legislation on Tuesday and sent it to President Donald Trump for his signature by the end of the year.Source: Shutterstock
- Zacks•5 months ago
The Zacks Analyst Blog Highlights: Vanguard Small-Cap Growth, iShares S&P Small-Cap 600 Growth and Vanguard S&P Small-Cap 600 Growth
The Zacks Analyst Blog Highlights: Vanguard Small-Cap Growth, iShares S&P Small-Cap 600 Growth and Vanguard S&P Small-Cap 600 Growth
- Zacks•5 months ago
3 Small-Cap Growth ETFs Surging to #1 Rank on Holiday Fervor
Small caps are the biggest beneficiaries of Trump???s tax cut plans and the booming economy.
- InvestorPlace•5 months ago
7 Vanguard ETFs to Build a Total Portfolio
When you’re putting together a portfolio — whether you’re starting one tomorrow, or you’re looking to tinker with what you’ve got — there are a few basics that most investors aim for: U.S. stocks. International holdings. Fixed income.
- Zacks•6 months ago
ETFs to Benefit from Trump Tax Plan
These ETFs will likely gain traction if Trump's tax plans see the day of light soon.
- Investor's Business Daily•7 months ago
Dow, S&P Hit Record Highs; Trump Plan Ignites Small-Cap Stocks
Key U.S. stock indexes turned mixed Monday even as small caps and biotechs continued to rally.
- Zacks•7 months ago
Hot Areas of Last Week and Their ETFs
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
- ETF Trends•7 months ago
Small-Cap ETFs for a More Risk-On Investor
Small-capitalization stock investors were defensive going into the 2017, but they have quickly changed their tune, turning to more growth-weighted smaller company picks. Investors can also gain diversified ...
- Market Realist•8 months ago
Nuplazid for Long-Term Care: Revenue Driver for Acadia?
Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.
- Market Realist•9 months ago
Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients
In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).
- Market Realist•9 months ago
Understanding Abiomed’s Changing Payment Structure Plans for Impella
Abiomed (ABMD) reported a ~100% reorder rate in fiscal 4Q17, amounting to around $103.3 million, which was 34% higher on a YoY basis.
- Motley Fool•10 months ago
Best Growth ETFs for 2017 and Beyond
Growth stock ETFs can allow you to profit from rapidly-growing companies while diversifying your risk.
- Market Realist•10 months ago
Understanding Align Technology’s Growing Position in International Markets
In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.
- Forbes•11 months ago
Unloved Sector Ready To Break Out?
As the market tries to digest the surprising UK election results and Thursday’s testimony by ex FBI chief James Comey there is one market sector that is starting to emerge as a new leader. Many Wall Street pros are either not bullish on the small cap stocks or are negative but why?
- Zacks•last year
Zacks Value Investor Highlights: Vanguard Small Cap Value ETF, Vanguard Small-Cap Growth ETF, CAI International, Energy Recovery and Rocky Brands
Zacks Value Investor Highlights: Vanguard Small Cap Value ETF, Vanguard Small-Cap Growth ETF, CAI International, Energy Recovery and Rocky Brands
- Zacks•last year
5 ETFs to Buy if Trump Tax Reform is Enacted by Year End
Trump Tax Reform Plans Put These ETFs in Focus.
- Market Realist•last year
Inside Exelixis’s Robust Growth Strategy for Cabometyx
Exelixis is now developing a strong sales team to support the commercial launch of Cabometyx for indications like first-line RCC and second-line HCC.
